Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
Hospital Universitario 12 De Octubre · National Cancer Centre Singapore · +22 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
521
total citations
- FWCI
- 50.87
- Percentile
- 100%
- References
- 28
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Gefitinib
- Afatinib
- Medicine
- Internal medicine
- Lung cancer
- Hazard ratio
- Oncology
- Epidermal growth factor receptor
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- IAInternational Association for the Study of Lung Cancer
- CCelgene
- VPVertex Pharmaceuticals
- ABACEA Biosciences
- COClovis Oncology
- AKAstraZeneca Korea
- CUChinese University of Hong Kong
- APAstellas Pharma
- OPOno Pharmaceutical
- GGenentech
- CPChugai Pharmaceutical